4:32 PM ET
8-K
Loan & Debt
Revolution Medicines $250M Debt Financing with Royalty Pharma Development Funding, LLC
Revolution Medicines drew down a $250 million Tranche A senior secured term loan from Royalty Pharma following the FDA approval of RASONQUE. The loan bears interest at a floating rate of three-month Term SOFR plus 5.75% and is due in full on October 8, 2032. The company also elected not to exercise an option to sell an additional $250 million royalty interest to Royalty Pharma.
- Value
- $250M
- Counterparty
- Royalty Pharma Development Funding, LLC
- Term
- through Oct 2032